BMS-707035

Data Sheet For research use only. Not for human use.

Cat. No. ：BCP02412CAS No. ：729607-74-3Purity：98%

Get Quotation Now

Tel: 0086-17754423994 or orders@biochempartner.com

* Required Fields.

Please complete the form below and you will get the price list in 1 minute.

* Required Fields.

Please complete the form below and we will contact you shortly.

* Required Fields.

Please complete the form below and we will contact you shortly.

CAS No.	729607-74-3	Cat. No.	BCP02412
Name	BMS-707035
Synonyms	BMS707035;BMS 707035;
SMILES
Chemical Name
Formula	C17H19FN4O5S	M. Wt	410.42
Purity	98%	Storage	Store at 4-8°C
Description	BMS-707035 is a pyrimidine carboxamide similar to Raltegravir, the first integrase inhibitor licensed for clinical use. BMS-707035 is a potent, specific, and reversible HIV-I integrase (IN) inhibitor that blocks HIV IN strand transfer activity with IC50 of 15 nM. [1] However, several IN mutations, including V75I, Q148R, V151I, and G163R are found to confer resistance to HIV IN inhibitors. The binding of BMS-707035 and target DNA to IN are mutually exclusive events, as revealed by the fact that the inhibition of strand transfer catalysis by BMS-707035 is overcome by increasing amount of target DNA. The binding affinity of BMS-707035 to IN is also affected by the four terminal bases at the 5' end of the pre-processed U5 long terminal repeat (LTR). Gln148 of IN is crucial for the binding of BMS-707035 to IN. The 3' terminus of the viral LTR, on the other hand, retards the rate of BMS-707035 association with IN, by regulating the kinetics of binding and dissociation.